Status:
TERMINATED
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
Lead Sponsor:
AstraZeneca
Conditions:
Cancer
Solid Tumors
Eligibility:
All Genders
20-74 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects expe...
Eligibility Criteria
Inclusion
- Japanese patients with advanced solid tumors for which standard treatment does not exist or is no longer effective.
- Must be suitable for treatment with gemcitabine
- Relatively good overall health other than cancer
Exclusion
- Poor bone marrow function (not producing enough blood cells).
- Poor liver or kidney function.
- Serious heart conditions
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00937664
Start Date
July 1 2009
End Date
February 1 2011
Last Update
February 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Minamiku, Fukuoka, Japan